Saurabh Mukherjea’s Marcellus Fund has added 5 stocks to the Rising Giants PMS portfolio

Grauer and Weil (G&W) enjoys a strong moat in its core Electroplating Chemicals business around: the recipe of the chemicals (IP), customising the product to the requirements of the customer and providing customer service through Pan-India technical centres. Consequently, there are strong entry barriers/barriers to scale in the industry with G&W and Artek being the only 2 large Indian companies alongside a few MNC players. Moreover, G&W has created strong competitive edge through backward integration into engineering electroplating equipments as well to the in-house manufacturing of certain intermediates

Avalon Technologies is expected to show strong revenue and profitability. Buy for target price of ₹920 (+30% upside): Motilal Oswal

Avalon Technologies (AVALON) reported a strong quarter, with revenue growing 37% YoY in 2QFY25, led by a healthy recovery in US operations (up 57% YoY) and consistent performance in the Indian business (up 16% YoY). Operating profitability improved (up 470bp) led by a shift in ~45- 50% of the US manufacturing operations to India and favorable operating leverage

Yatharth Hospital has significant growth opportunities. Buy for target price of ₹790 (30% upside): SMIFS

Yatharth Hospitals reported a healthy revenue growth which was marginally below our estimates, while EBITDA was slightly below our expectations due to increased employee cost on recruiting leading doctors in the NCR region during Q2FY25

J.B. Chemicals is well-positioned to capitalize on immediate growth opportunities. Buy for target price of ₹2217 (19% upside): SMIFS

JBCP is well-positioned to capitalize on immediate growth opportunities. We expect 29% EPS CAGR over FY24-26E aided by 1) Strong growth from domestic business (CAGR of 15% FY24-FY27E), 2) ~30% growth over FY24-FY26E from acquired portfolios, 3) scaling up of high margin CDMO business on the back of new therapy launches and 4) robust FCF generation. We maintain our Buy rating on the stock with similar target price to Rs 2,217, valuing the company at 36x Sept’26E EPS

Aptus Value Housing Finance has significant headroom for growth. Buy for target price of ₹425 (25% upside): Systematix Research

APTUS reported a healthy quarter led by pick up in disbursements, steady spreads and asset quality. Management remained confident of maintaining strong AUM growth and stable asset quality in FY25. APTUS’s core strengths and prudent underwriting practice provide comfort. At CMP the stock is trading at 3.4x FY26 BV with RoA/ RoE of 7%/ 21%. We maintain our BUY rating on the stock with an unchanged target price of Rs. 425, valuing the company at 4.2x FY26E book value.

PCBL has organic levers of growth amidst changing business profile. Buy for target price of ₹600 (45% upside): ICICI Direct

PCBL Ltd (erstwhile Phillips Carbon Black) is the leading manufacturer of carbon black, which is used as a reinforcing material in tyres

The Axis Top Picks Basket delivered a return of 11.6% in the last six months against the 7.5% returns posted by Nifty 50 over the same period

The Axis Top Picks Basket delivered a return of 11.6% in the last six months against the 7.5% returns posted by Nifty 50 over the same period. Amidst a highly volatile month of Oct’24 that witnessed notably mixed performance across sectors, market caps, and style indices, the Axis Top Picks basket declined by 4.4% in Oct’24 (Till 1st Nov’24 closing) but managed to beat the market performance as the benchmark Nifty 50 declined by 5.8% over the same period.

Shalby is making right strides with calibrated growth. Buy for target price of ₹310 (35% upside): ICICI Direct

Started by renowned orthopaedic surgeon Dr Vikram Shah, Shalby is a multi-specialty hospitals chain with expertise in joint replacement.

Dividend Yield Monitor 2nd November 2024 by SBI Securities

The dividend yield is computed based on the closing price of 1st November 2024. We have considered companies that have consistently paid dividend in the last 3 years – i.e FY24/CY23, FY23/CY22and FY22/CY21. The * mark indicates data for CY23. The **mark indicates data for year ending Jun’23

DLF has a strong growth story given its robust launch pipeline. Buy for target price of ₹1081 (30% upside): Nuvama

We remain upbeat on DLFU’s growth prospects on strong sectoral tailwinds (industry-wide consolidation, record low inventory in its home market, and greater preference for branded luxury inventory), an extensive launch pipeline, and expansion in its annuity portfolio. A strong Balance Sheet, with consistent cash flow, lends comfort. We revise our TP to INR1,081 (INR1,087 earlier). Maintain ‘BUY’.